Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MethARO
- Development stage
- Phase 2
- Lead developer
- SafeRx Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MethARO is a proprietary oral, immediate-release fixed-dose combination of methadone hydrochloride and disulfiram being developed by SafeRx as an Alcohol-Resistant Opioid product. Methadone is intended to provide mu-opioid receptor agonism for opioid use disorder and/or analgesia, while disulfiram inhibits aldehyde dehydrogenase and is intended to deter alcohol consumption through an aversive alcohol-disulfiram reaction. The product uses a matrix-based tablet designed to prevent separation of its two active ingredients and is intended for opioid use disorder and moderate-to-severe pain refractory to non-opioid therapy when enforced alcohol sobriety is desired. (saferxpharmaceuticals.com)
- Other names
- MethAROMethARO IR
02
Targets
Beyond the preview
Go deeper on MethARO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MethARO.